<HashMap><database>biostudies-arrayexpress</database><scores/><additional><submitter>Steffen Möller</submitter><organism>Homo sapiens</organism><software>DRAGEN BCL Convert (https://support.illumina.com/sequencing/sequencing_software/bcl-convert/) and quality-checked using FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/).</software><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/E-MTAB-15709</full_dataset_link><description>All p73 isoforms share an identical DNA-binding domain. These CUT&amp;RUN datasets for TAp73α, DNp73β, and a GFP control illustrate the isoform-specific differences in genomic binding. As no antibodies are currently available that selectively recognize individual p73 variants, the data were generated following overexpression of the individual variant.</description><repository>biostudies-arrayexpress</repository><sample_protocol>Sequencing - Loading concentration of 750 pM on a NextSeq 1000/2000 system using a P1 flow cell according to manufacturer's instructions.</sample_protocol><sample_protocol>Nucleic Acid Extraction - Immunoprecipitation was performed with p73 antibody (1:1000; Thermo Fisher Scientific, USA)</sample_protocol><sample_protocol>Sample Collection - CUT&amp;RUN assays were conducted on SK-Mel-29 melanoma cells transduced with Ad.TAp73α, Ad.DNp73β or the Ad.GFP control, following the manufacturer’s protocol (CUT&amp;RUN Assay Kit, Cell Signaling, USA).</sample_protocol><sample_protocol>Sample Treatment - Adenoviral vectors encoding TAp73α, DNp73β, or GFP have been reported previously (Stiewe et al. 2002; Buhlmann et al. 2008). Infections of SK-Mel-29 were performed at a multiplicity of infection selected to achieve 100% transduction of the target cells.</sample_protocol><sample_protocol>Library Construction - libraries were prepared with the DNA Library Prep Kit for Illumina Systems (Cell Signaling, USA) according to the instructions</sample_protocol><sample_protocol>Growth Protocol - Human SK-Mel-29 and SaOS-2 cell lines were maintained at 37 °C in a humidified atmosphere with 5% CO₂ in Dulbecco’s modified Eagle’s medium (DMEM; PAN-Biotech, Germany), containing pyruvate for SK-Mel-29 and pyruvate-free for SaOS-2. Media were supplemented with 10% fetal calf serum (FCS; PAN-Biotech, Germany), 0.1 mM non-essential amino acids, 50 U/mL penicillin, and 50 µg/mL streptomycin.</sample_protocol><figure_sub>Organization</figure_sub><figure_sub>MINSEQE Score</figure_sub><figure_sub>Assays and Data</figure_sub><figure_sub>MAGE-TAB Files</figure_sub><omics_type>Metabolomics</omics_type><omics_type>Unknown</omics_type><omics_type>Transcriptomics</omics_type><omics_type>Genomics</omics_type><omics_type>Proteomics</omics_type><instrument_platform>NextSeq 2000</instrument_platform><study_type>CUT&amp;RUN</study_type><species>Homo sapiens</species><pubmed_title>TAp73α drives cancer metastasis via PPI-mediated derepression of the neuronal HDAC2/REST-GABBR2 axis.</pubmed_title><pubmed_title>Integrative Multimodal Profiling of TAp73 and DNp73 Reveals Isoform-Specific Transcriptomic Coregulator Landscapes in Cancer Programs.</pubmed_title><pubmed_authors>Steffen Möller</pubmed_authors><pubmed_authors>Nares Trakooljul</pubmed_authors><pubmed_authors>Murr N, Richter C, Gupta SK, Hammer E, Trakooljul N, Stoll A, Möller S, Neumann LE, Pützer BM, Spitschak A.</pubmed_authors><pubmed_authors>Möller S, Spitschak A, Murr N, Pützer BM.</pubmed_authors><pubmed_authors>Nico Murr</pubmed_authors><pubmed_authors>Alf Spitschak</pubmed_authors></additional><is_claimable>false</is_claimable><name>Binding of full length p73 (TAp73alpha) and cancer-specific variant (DNp73beta) to genome of melanoma cell line SK-Mel-29</name><description>All p73 isoforms share an identical DNA-binding domain. These CUT&amp;RUN datasets for TAp73α, DNp73β, and a GFP control illustrate the isoform-specific differences in genomic binding. As no antibodies are currently available that selectively recognize individual p73 variants, the data were generated following overexpression of the individual variant.</description><dates><release>2026-03-30T00:00:00Z</release><modification>2026-04-21T15:09:55.286Z</modification><creation>2025-10-13T15:57:31.398Z</creation></dates><accession>E-MTAB-15709</accession><cross_references><pubmed>publ-0-mohi-removable</pubmed><pubmed>publ-0-02hq-removable</pubmed><ENA>ERP182066</ENA><Biostudies>E-MTAB-14704</Biostudies><EFO>EFO_0002944</EFO><EFO>EFO_0009973</EFO><EFO>EFO_0004170</EFO><EFO>EFO_0003789</EFO><EFO>EFO_0005518</EFO><EFO>EFO_0004184</EFO><EFO>EFO_0003969</EFO><doi>10.1016/j.canlet.2025.217867</doi><doi>10.3390/biom16010063</doi></cross_references></HashMap>